Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma  by Best, Jennie H. et al.
Volume 8 • Number 4 • 2005
V A L U E  I N  H E A L T H
© ISPOR 1098-3015/05/2005 462–470 462
doi:10.1111/j.1524-4733.2005.00037.x
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 Blackwell Publishing84462470Original ArticleEconomics of Rituximab in DLBCLBest et al.
Address correspondence to: Jennie Best, Department of Phar-
macy, University of Washington, Box 357630, Seattle, WA,
USA 98195. E-mail: bestj@u.washington.edu
Cost-Effectiveness Analysis of Rituximab Combined with 
CHOP for Treatment of Diffuse Large B-Cell Lymphoma
Jennie H. Best, MA,1 John Hornberger, MD, MS,2,3 Stephen J. Proctor, FRCP, FRCPath,4 
Louis F. Omnes, MA,5 Fred Jost, MSc6
1Department of Pharmacy, University of Washington, Seattle, WA, USA; 2Internal Medicine, Stanford University School of Medicine, 
Stanford, CA, USA; 3The SPHERE Institute/Acumen, LLC, Burlingame, CA, USA; 4Royal Victoria Inﬁrmary, Department of Haematology, 
School of Clinical and Laboratory Sciences, Newcastle-upon-Tyne, UK, 5Annie Chicoye Economics, Neuilly sur Seine, France; 
6F. Hoffmann-La Roche Ltd., Basel, Switzerland
ABSTRACT
Purpose: To estimate the cost-effectiveness from a French
payer perspective of CHOP (cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) alone compared with
CHOP plus rituximab (R-CHOP) for treatment of pa-
tients with diffuse large B-cell lymphoma.
Methods: Mean patient survival, days of hospitalization,
and chemotherapy costs during treatment were estimated
from a Phase III trial in France, Belgium, and Switzerland.
Survival during the trial was estimated using the Kaplan–
Meier method; survival beyond the trial period was pro-
jected based on mortality rates from the Scottish and
Newcastle Lymphoma Group database. French diagnosis-
related group (DRG) payment schedules were applied to
trial data to estimate cost of adverse events and drug
administration. We estimated survival and cost-effective-
ness [the incremental cost per quality-adjusted life-year
(QALY) gained] from 4 years (median clinical trial fol-
low-up period) to 15 years, discounted at a ﬁxed annual
rate of 3%. We used published patient preferences. We
converted currency to euros, based on 2003 exchange
rates.
Results: R-CHOP resulted in a 20.6% relative increase in
complete response rate (absolute increase from 63% to
76%), and a 31% decrease in risk of death at 4 years
(95% CI 8–49%). Over a 15-year time horizon, mean
overall survival (OS) duration was estimated to be
6.90 years for R-CHOP and 5.74 years for CHOP, a
mean increase in OS of 1.16 years (or 1.07 QALYs). Total
direct medical costs were €13,170 higher with R-CHOP,
with an incremental cost-effectiveness ratio of €12,259
per QALY gained.
Conclusion: R-CHOP signiﬁcantly increases mean OS up
to 4 years compared with CHOP, and its cost-effective-
ness ratio compares favorably with other oncology treat-
ments in widespread use.
Keywords: cost-effectiveness analysis, economics, lym-
phoma, rituximab.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common non-Hodgkin’s lymphoma (NHL). Before
the advent of CHOP (cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) chemotherapy in
the 1970s, DLBCL resulted in a patient’s death
within weeks or months of diagnosis [1]. Neverthe-
less, with CHOP chemotherapy, a complete
response (CR) is achievable in approximately 50%
of patients and disease-free survival (DFS) occurs in
30% to 40% of patients [2]. The success of these
regimens has encouraged research to increase
response rates and prolong survival [3–5].
Patients aged 60 and older constitute a substan-
tial proportion of patients with DLBCL, and they
experience worse outcomes than patients aged 60
and younger [6]. Attempts to modify regimens to
reduce toxicity while maintaining the survival ben-
eﬁts of CHOP in elderly patients have met with lim-
ited success [7–9].
In the late 1990s, rituximab (MabThera®,
Roche, Switzerland), a chimeric anti-CD20 IgG1
monoclonal antibody, emerged as a novel treatment
for the management of patients with relapsing indo-
lent or aggressive lymphoma [10–12]. Phase II stud-
ies of rituximab in combination with CHOP in
patients with intermediate grade NHL showed a
comparable safety proﬁle to CHOP and response
rates in excess of 90% [13]. A phase III trial of 399
elderly patients (older than 60 years) with DLBCL,
conducted by the Groupe d’Etude des Lymphomes
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de l’Adulte (GELA LNH 98-5), showed that the
addition of rituximab to an 8-week CHOP regimen
increases the CR rate from 63% to 76% [14], and
reduced the risk of death by 33% at 3-year median
follow-up [15].
Because of rising health-care utilization and
expenditures relative to other public policy goods
and services, there is increased policy interest in
forecasting outcomes and economic consequences
of novel therapeutic options in oncology [16,17]. In
this study, we forecast the effects of rituximab plus
CHOP compared with CHOP on years of life
gained and health-care costs, and estimate cost-
effectiveness.
Methods
We developed a model that applies to patients aged
60 to 80 that have untreated DLBCL with stage II,
III, or IV disease and a performance status of 0 to 2
according to the criteria of the Eastern Clinical
Oncology Group. A representative, or “reference-
case” patient [18–20] is assumed to have the initial
characteristics (age, performance status, stage of ill-
ness, B symptoms, number of extranodal sites, bone
marrow involvement and age-adjusted IPI score) as
the average patient in the LNH 98-5 trial [14].
Characteristics of patients enrolled in LNH 98-5 are
summarized in Table 1.
The analyses compare two treatments: 1) CHOP,
or 2) rituximab plus CHOP (R-CHOP). CHOP
consisted of a combination of cyclophosphamide,
750 mg/m2 on day 1; doxorubicin, 50 mg/m2 on day
1; vincristine, 1.4 mg/m2, up to a maximal dose of
2 mg, on day 1; and prednisone 40 mg/m2/day for
5 days. CHOP was administered every 3 weeks for
eight cycles. R-CHOP consisted of CHOP plus
rituximab, 375 mg/m2, on day 1 of each of the 8
cycles of CHOP. Doses of cyclophosphamide and
doxorubicin were adjusted for toxicity [14]. The
doses of rituximab were not modiﬁed, but rituxi-
mab was discontinued when CHOP was stopped.
Treatment also was stopped if progression of the
lymphoma or severe toxicity occurred.
Data Sources
Three data sources were used for the model. Our
ﬁrst data source was the LNH 98-5 trial data;
details about the trial design and primary clini-
cal ﬁndings are published elsewhere [14]. We
used the LNH 98-5 data to estimate 1) mean
overall and DFS; 2) incidence of hospitalizations
for adverse events and drug administration; and
3) the cumulative doses of chemotherapeutic
agents.
Our second data source was the Scottish and
Newcastle Lymphoma Group (SNLG) database,
used to estimate the tail of the survival distribution
beyond the 48 months of median follow-up of the
LNH 98-5 data. The SNLG database was estab-
lished in 1979. Since 1994, it has captured compre-
hensive data on treatment and outcomes on more
than 95% of the lymphomas presenting in a popu-
lation of 8.5 million [21]. Approximately 1000 new
patients are added to the database each year, with
participating clinicians providing a yearly update on
existing patients. The SNLG team provided data on
1359 patients with DLBCL/high-grade lymphoma
who were treated with CHOP, with a median age of
63 years (53.6% of the patients were younger than
65 years of age; 16.7% were older than 75 years of
age). The SNLG database used the Kiel classiﬁca-
tion until 1995, under which DLBCL patients
would have made up the majority of high-grade
lymphoma patients. The CR rates, DFS, and overall
Table 1 Characteristics of patients in trial GELA LNH 98-
5 of treatment of diffuse large B-cell lymphoma and patients
treated with CHOP for high-grade lymphoma/diffuse large B-
cell lymphoma in the Scottish and Newcastle Lymphoma
Group (SNLG) database
Characteristic
GELA LNH
98-5 CHOP R-CHOP
SNLG
CHOP
Number of patients 197 202 816
Age (year)*
<65 24% 22% 23%
65–69 31% 28% 24%
70–74 28% 26% 25%
≥75 16% 24% 18%
Female 46% 54% 49%
Performance status*
0 36% 33% 28%
1 48% 45% 45%
>1 17% 22% 27%
Stage*
I 1% 0 25%
II 20% 20% 22%
III 15% 16% 20%
IV 65% 63% 33%
B symptoms 36% 39% NA
Number of extranodal sites
0 22% 23% NA
1 52% 47%
>2 26% 30%
Age-adjusted International 
Prognostic Index score
0 11% 10% 25%
1 28% 30% 30%
2 48% 43% 25%
3 13% 17% 20%
Performance status was deﬁned according to the criteria of the Eastern
Cooperative Oncology Group (with an increasing score indicating declining
performance).
*Percentages do not add to 100% because of rounding.
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survival (OS) for the 816 patients aged 60 and
above who received CHOP are shown in Table 2.
To be consistent with the age distribution in the
GELA trial we used the data for the persons aged
60 years and above to estimate OS and DFS beyond
the trial period. Characteristics of the 816 patients
are shown in Table 1.
Third and last, we used published data to
estimate the costs associated with cancer surveil-
lance care (routine monitoring), salvage therapy
(intensive chemotherapy only), bone marrow trans-
plantation, end-of-life care (palliative care), hospi-
talizations for drug administration and adverse
events, and chemotherapy acquisition costs, and to
determine adjustments for quality of life.
Analyses
Survival
Survival data were collected for as many patients as
possible. Where no additional data were available,
patients were to be censored at the date last seen.
All patients who were alive after the last database
closure on January 31, 2002 were to be contacted
by the GELA LNH 98-5 study team and informa-
tion was obtained about their survival status.
All randomized patients (N = 399) were included
in the survival update analysis and the data cut-off
was July 1, 2003. The median follow-up time,
deﬁned for all patients alive as the difference
between date of randomization and date of last
contact, was 1475 days (approximately 48
months). Median observation time was similar in
the two treatment groups: 1485 days in the CHOP
group and 1464 days in the R-CHOP group. All
patients, except one patient, had a follow-up of
more than 36 months. About one third of the pop-
ulation was followed for 48 months or longer.
The relative risk of death among CHOP-treated
patients in SNLG was 9% higher than for patients
treated with CHOP in LNH 98-5. To forecast sur-
vival with CHOP, we recalibrated the mortality
risks from SNLG to match those observed in LNH
98-5. Outcomes in nontrial settings may not reﬂect
those found in trials, so we tested in further analyses
whether the forecasts were sensitive to this calibra-
tion. The effect of R-CHOP mortality risk was
based on the 31% further reduction estimated from
the 4-year follow-up analyses. Response rates were
based on the LNH 98-5 data. Because of the limited
number of patients observed in SNLG after 15
years, we used 15 years for the forecast period, or
time horizon.
Mortality rates in both CHOP and R-CHOP
after 48 months were based on rates derived from
CHOP-treated patients in the SNLG database. This
implies that R-CHOP has no beneﬁt compared with
CHOP on risk of death beyond the 4-year update of
the LNH 98-5 trial. The survival curve is shown in
Figure 1. We estimated DFS for patients with CR,
from the date of randomization to the date of the
ﬁrst relapse.
For some patients aged 60 and older who fail to
achieve a response, an option is “salvage” treatment
with high-dose chemotherapy with or without radi-
ation therapy. Some patients also may be eligible for
transplantation [22]. In a selected population of
patients who relapse, mortality rates of transplan-
tation compared with conventional therapy were
reduced by 30% [23]. Other studies have conﬁrmed
the beneﬁts of various transplantation techniques in
patients who fail to respond to primary therapy
Table 2 Outcomes after treatment with CHOP for high-grade lymphoma/DLBCL among patients aged 60 or more in the
Scottish and Newcastle Lymphoma Group database
Complete response rate
Disease-free survival for patients achieving complete 
response (months)* Overall survival (months)*
Median (95% CI) Mean (95% CI) Median (95% CI) Mean (95% CI)
62.1% Not reached at 140 months 87 (79.5–95.6) 33 (26.1–39.9) 55 (50.1–60.8)
*Kaplan–Meier estimates; restricted means were calculated.
CI, conﬁdence interval; DLBCL, diffuse large B-cell lymphoma.
Figure 1 Survival (trial-based up to 4 years and projected using Scot-
tish and Newcastle Lymphoma Group data). CHOP, cyclophospha-
mide, doxorubicin, vincristine, and prednisone.
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[24–26]. Before the advent of transplantation, mean
survival of elderly patients who failed to respond to
primary treatment was 1 to 1.5 years [6]. Based on
the 4-year LNH 98-5 data, we assumed that salvage
therapy (intensive chemotherapy only) would be
offered to 25% of R-CHOP patients and 43% of
CHOP patients who failed to respond to primary
therapy. Salvage therapy was assumed to increase
OS an additional 0.5 years [27]. One patient in the
LNH 98-5 trial received transplantation; for the
base case, we assumed 0% probability of receiving
transplantation in the French setting.
Quality-Adjusted Survival
Survival was partitioned into two periods: DFS and
postprogression survival. Mean DFS was computed
as the product of the CR rate and mean time to pro-
gression among patients with CR. Postprogression
survival was computed as the difference of mean OS
and mean DFS. We adjusted outcomes for quality of
life using published utility estimates (scaled between
0 for death and 1 for normal health) [28–30, J. K.
Doorduijn, et al., pers. comm., 2003]. For our base
case analysis, we calculated utility scores for DFS
and progression based on a study by Doorduijn
et al. of 132 of 411 patients aged 65 to 90 with
aggressive NHL who were entered into a rand-
omized multicenter study comparing CHOP with
CHOP plus G-CSF [28, J. K. Doorduijn, et al., pers.
comm., 2003]. We weighted the 3-month utility
scores from Doorduijn et al.’s study [28] by the pro-
portion of patients in the GELA study who had a
CR and no CR/progression to obtain a utility score
of 0.83 for DFS and 0.39 for progression. We
accounted for a wide range in utility scores in our
sensitivity analyses.
Costs
The cost of cancer surveillance was estimated to
equal €308 per year [31]. Chemotherapy adminis-
tration costs were calculated by estimating drug
acquisition costs and costs of administering the
drug. All chemotherapy was administered at the
hospital—as inpatient (i.e., spent at least one night
in the hospital) or outpatient (patient did not stay in
hospital overnight). LNH 98-5 ﬁles were analyzed
to assess whether a patient was hospitalized, the
reason for hospitalization, and total days of hospi-
talization per cycle. Each adverse event requiring
hospitalization was classiﬁed by the principle diag-
nosis using the International Statistical Classiﬁca-
tion of Diseases (Version 10, WHO, 2003) [32], and
as outpatient or inpatient, based on length of stay.
Hospital admission data collection in LNH 98-5
occurred only until the treatment period or the
patient chose to drop out of the trial.
The complete costs in euro in 2003 of the French
diagnosis-related groups (DRGs) were used to esti-
mate hospitalization costs for drug administration
and treatment of adverse events. Patient admissions
for chemotherapy administration and adverse
events were classiﬁed in a DRG based on his/her
principle diagnosis and length of stay, inpatient or
outpatient DRG. When several adverse events in the
same cycle leading to a hospitalization were docu-
mented for a patient a Delphi panel consisting of 5
GELA and Groupe Ouest-Est d’étude des leucémies
et autres maladies du sang (GOELAMS) members
selected the hospitalization principle diagnosis. The
complete cost per DRG was estimated, including a
daily cost component (ﬁxed costs) and a variable
cost component (direct medical costs) [33]. The the-
oretical cost of a stay was developed based on the
DRG where a patient was classiﬁed, its length of
stay, and speciﬁc information related to the drug
acquisition costs.
Two studies have reported costs in Europe of
transplantation for lymphoma. In France, Perrier
et al. reported an average cost per patient of
€34,630 for autologous blood progenitor cell trans-
plantation for 95 patients with lymphoma, includ-
ing costs for mobilization, treatment period, and
secondary hospitalization [34]. In The Netherlands,
van Agthoven et al. reported costs of €15,000 to
€19,000 for patients undergoing autologous periph-
eral blood stem cell transplantation or autologous
bone marrow transplantation, respectively, for
refractory or relapsed non-Hodgkin’s lymphoma or
Hodgkin’s disease [35]. In the base case, no patients
received transplantation. We used €15,000 for the
cost of high-dose chemotherapy after relapse. In
sensitivity analyses, we applied a cost of €34,630
and probability of 3% to 8% for transplantation in
the event of nonresponse. We also assumed that
end-of-life and palliation care was €15,000. All
costs were converted to euro based on exchange
rate of €1 equals 6.56 French francs in 2003 [36].
Perspective, Cost-Effectiveness, and Other Analyses
The analysis was performed from the perspective
of the French Social Security system (i.e., French
payer). The French Social Security funds public hos-
pitals through DRGs and reimburses certain inno-
vative drugs to the hospital. Patients pay a small fee
per day for a hospitalization, which is generally
fully funded by a third party payer (private insur-
ance). In many instances, priority is given to inter-
ventions that improve survival, with economic
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considerations focusing on direct medical costs.
Cost-effectiveness thus was estimated as the differ-
ence in direct medical costs between R-CHOP and
CHOP divided by the difference in mean survival
between the two regimens. All costs and beneﬁts
were discounted at a ﬁxed annual rate of 3%, a
standard method used in economic evaluation to
account for time preferences [18–20].
We determined distributions for each of the key
variables using either a uniform or normal distri-
bution. Probabilistic simulation analyses were
conducted to estimate the impact of varying all
assumptions simultaneously. In one-way sensitivity
analysis, we looked at the effect of each variable
independently when assigned extreme values of
their distributions. For uniform distribution, we
used the highest and lowest values in the distribu-
tion. For normal distributions, we used the 5th and
95th percentiles of the distributions.
Results
Overall and DFS
The relative risk of death over 4 years was reduced
by 31% in the R-CHOP group (univariate Cox
regression, 95% CI 8–49%). Kaplan–Meier esti-
mates of the survival rates at 12 months were
69.5% for CHOP and 82.7% for R-CHOP. At
24 months, the difference was less pronounced but
still present: 57% in CHOP compared with 70% in
R-CHOP [14]. Thereafter, there was little change in
the survival rates. At 4 years, 47.2% of patients
receiving CHOP were alive, compared with 59.6%
receiving R-CHOP. In 48 months of follow-up in
the LNH 98-5 study, the mean difference in OS
between R-CHOP and CHOP was 0.33 years. Pro-
jected to 15 years, R-CHOP resulted in mean OS of
6.90 years compared with 5.74 years in mean OS
for CHOP, mean difference in OS equal to 1.16
undiscounted years (or 1.00 discounted years, as
shown in Table 3).
R-CHOP increased CR rate by an absolute of
13%, from 63% for CHOP to 76% for R-CHOP.
R-CHOP also reduced the relative risk of relapse
among patients with CR by 43.9% (univariate Cox
regression, 95% CI 19–61%) after 4 years. Consid-
ering the higher response rate and longer duration
until relapse associated with R-CHOP, the mean
DFS increased from 4.39 years to 6.27 years, for a
mean difference of 1.88 undiscounted years over
15 years. Non-DFS was projected to be 1.27 years
for CHOP compared with 0.59 for R-CHOP, for a
mean difference of 0.68 years (undiscounted) over
15 years. R-CHOP resulted in 5.45 quality-adjusted
life-years (QALYs) compared with 4.17 QALYs for
CHOP, for a difference of 1.28 QALYs, undis-
counted (or 1.07 discounted QALYs).
Hospitalizations, Costs, and Cost-Effectiveness
The mean total cost of chemotherapy agents for the
R-CHOP group was €14,364 higher than for
CHOP (Table 4). Patients receiving R-CHOP com-
pleted more courses of chemotherapy, on average
(7.5 courses), compared with CHOP patients (7.1
courses) because patients receiving CHOP pro-
gressed more often on therapy than R-CHOP-
treated patients. Thus, the cost of hospitalization
related to chemotherapy was higher for R-CHOP
patients.
Table 5 shows the adverse events that occurred in
the trial during the treatment period and were used
in the analysis; only events that occurred in at least
ﬁve patients are shown. There was no difference in
costs for hospitalizations for adverse events based
on DRG payment schedules for speciﬁc diagnoses.
Patients receiving R-CHOP had slightly fewer days
in hospital during the 6-month treatment period.
The average number of hospitalizations without an
overnight stay was 15.1 for CHOP, compared with
14.7 for R-CHOP patients. The average number of
inpatient hospitalization days was 5.4 for CHOP
compared with 4.9 for R-CHOP patients. Based
on DRG methods, overall, mean hospital costs
Table 3 Discounted survival results over 15-year time
horizon (years)
Category CHOP R-CHOP
Disease-free survival 3.80 5.40
Non–disease-free survival 1.04 0.44
Total years of survival 4.84 5.83
Quality-adjusted life-years 3.59 4.66
Table 4 Mean costs of CHOP versus R-CHOP (2003 euro)
for treatment of diffuse large B-cell lymphoma over 15 years
Category
CHOP
(€)
R-CHOP
(€)
Drug acquisition
CHOP 4,747 5,016
Rituximab 14,095
Hospitalization
For adverse events 3,097 3,014
For chemotherapy 5,802 6,764
Surveillance 1,846 2,188
Salvage therapy (high dose chemotherapy) 2,358 890
End-of-life 10,932 9,984
Total 28,782 41,952
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP,
rituximab plus CHOP.
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increased by €879. Post-treatment surveillance
increased costs by €342. Mean salvage therapy costs
decreased by €1468 and end-of-life care decreased
by €948.
Total direct medical costs increased with R-
CHOP by €13,170 over 15 years. The incremental
cost-effectiveness for 4 years (the median follow-up
currently available for the trial) was €37,168 per
life-year gained and €29,976 per QALY gained. The
incremental cost-effectiveness at 15 years was esti-
mated to be €11,392 per life-year gained and
€12,259 per QALY gained.
Sensitivity Analyses
We conducted further analyses to determine if R-
CHOP may be more or less cost-effective under less
likely scenarios using one-way and probabilistic
sensitivity analyses (Table 6). The most inﬂuential
variable on cost-effectiveness in the analysis was
the time horizon. When using a 4-year horizon, the
cost-effectiveness ratio equaled €29,976 per QALY
gained, compared with €17,120 and €12,259 when
using an 8-year or 15-year horizon, respectively.
Other variables had little inﬂuence on the cost-effec-
tiveness ratio, all being less than €17,000. In prob-
abilistic analyses, which simulate the parameters’
probabilistic distributions, the 5th and 95th percen-
tiles of the cost-utility distribution were €6,818 and
€22,789, respectively (Fig. 2).
Discussion
The addition of rituximab to CHOP was shown in
a phase III trial to signiﬁcantly improve the rate of
CR and duration of event-free survival, DFS, and
OS for elderly patients with DLBCL. R-CHOP also
was well tolerated, had a similar incidence of seri-
Table 5 Diagnoses and incidence*, by diagnosis-related
group (DRG)
DRG Diagnosis
Incidence 
CHOP
(N = 197)
R-CHOP
(N = 202)
571 Aplasia 25 26
570 Anemia 24 17
129 Broncho-pneumopathy 11 6
604 Septicemia 10 0
574 Febrile neutropenia 10 13
607 Fever 10 0
671 Health status alteration—asthenia 7 6
418 Diabetes 6 0
256 Abdominal and gastric pains 5 5
604 Septic shock 0 9
136 Bronchospasm 0 7
187 Phlebitis 0 5
*Diagnoses included if at least 5 occurrences.
Table 6 Results of one-way sensitivity analyses (euro)
Variable
Base case
estimate Range
Cost per quality 
adjusted life-year 
gained (€) 
Time horizon (years) 15 4 15 29,976 12,259
Rituximab cost per cycle 1,914 1,665 2,201 10,552 14,427
Utility for disease-free 0.83 0.72 0.95 14,663 10,399
Utility for progression 0.39 0.34 0.83 11,898 16,736
Discount rate (%) 3 0 5 10,519 13,497
Relative risk reduction in disease-free survival (%) 43.9 38 51 12,839 11,616
Relative risk reduction in overall survival (%) 31 27 36 13,051 11,350
Relative increase in complete response rates (%) 20.6 18 24 12,922 11,481
Salvage therapy cost (high-dose chemotherapy) 15,000 5,000 25,000 13,170 11,348
Probability of receiving salvage
R-CHOP (%) 25 — 43 12,756 —
CHOP (%) 43 25 — — 13,021
Life extension with salvage therapy 0.5 0 1 11,915 12,624
Surveillance costs per year 308 0 525 11,940 12,484
CHOP cost per cycle 672 585 773 12,227 12,297
Probability that patients who receive salvage therapy also
get transplantation (%); transplantation costs = 34,630
0 — 3 12,259 12,165
Probability that patients who receive salvage therapy also 
get transplantation (%); transplantation costs = 34,630
0 — 8 12,259 12,007
Probability that patients who receive salvage therapy also 
get transplantation (%); transplantation costs = 40,000
0 — 8 12,259 11,968
End-of-life care 15,000 5,000 25,000 12,847 11,671
Future unrelated medical costs 0 0 5,000 12,259 17,438
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus CHOP.
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ous adverse events compared with CHOP, and more
patients were able to complete all eight courses of
chemotherapy [14]. The economic analyses pre-
sented here show that R-CHOP has a projected
cost-effectiveness ratio less than €20,000 per QALY
gained.
Numerous economic analyses have been con-
ducted in oncology [15]. No cost-effectiveness stud-
ies have been published for DLBCL, but there exist
studies for other hematological malignancies. The
cost-effectiveness of interferon-alpha therapy versus
hydoxyurea therapy for chronic myelogenous
leukemia (CML) was estimated to be $37,000 per
QALY gained for a representative 50-year-old
patient with median duration survival of 69 and
58 months, respectively [15,37]. Interferon alpha
for CML increased quality-adjusted life expectancy
by 15.5 months compared with conventional chem-
otherapy, for a cost per QALY of $96,000 [15–38].
Messori estimated that maintenance treatment for
CML with interferon improved lifetime survival
from 56 to 93 years (discounted) per 100 patients
compared with busulfan or hydroxyurea, at
$226,000 per life-year gained [39].
A key issue of this analysis was how long to
model survival beyond the end of the trial. Interna-
tional economic guidelines recommend assessing
implications of lifetime forecasts [40], allowing all
potential beneﬁts and costs to be considered. This is
of particular relevance for R-CHOP because most
of the costs are incurred within the ﬁrst 6 months,
but the beneﬁt in survival persists at the median
follow-up of 4 years. The longest time horizon in
our analyses was 15 years, where at least 20% of
patients in low-risk subgroups are likely to be alive
at the end of 15 years [6].
A survival advantage persisted more than 4 years
after last dose of R-CHOP was administered in the
LNH 98-5 trial, thereby suggesting the possibility
of increasing the rate of cures and, thus, long-term
DFS. There exists no published consensus about
how long a patient should be followed before con-
ﬁdently claiming that a patient is cured. Fisher et al.
considered a patient cured if he had not experienced
a relapse or death by 2 years [41]. Armitage et al.
reported that a continuous remission for 2 years has
approximately 70% to 90% likelihood of maintain-
ing a durable cure [42]. By contrast, Frei et al.
stated that the DFS needed to be maintained up to
4 years [43]. In Shipp et al. the mortality rates
declined to baseline at 3 to 4 years after initiating
treatment [6]. Lee et al. found that patients with
advanced-stage diffuse large-cell lymphoma treated
with MACOP-B had a 78% chance of being in
remission at 10 years if they were in remission after
2 years [44]. Additional follow-up is warranted to
learn whether the persistent survival advantage of
R-CHOP found at 4 years translates into long-term
cures of DLBCL.
Costs, costing methodologies, and treatment
patterns vary by different settings and patient
populations (e.g., by center, country, and patient
subgroups) [45]. The cost-effectiveness results may
not be generalizable to other countries or to other
patient populations. Economic analyses from addi-
tional studies will help to further reﬁne the cost-
effectiveness of R-CHOP.
Adding rituximab to CHOP signiﬁcantly
improves survival for elderly patients with DLBCL.
R-CHOP is even cost-effective [46,47] during the
period observed in the trial and compares favorably
with other oncology treatments [16]. If the survival
advantage persists on further follow-up, then ritux-
imab will be among the more cost-effective thera-
pies available in oncology.
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